Business
Late-Breaking Data from PRESERVE Trial Evaluates XVIVO’s HOPE Preservation Approach in Heart Transplantation
TORONTO, April 22, 2026--XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation
About this update from Xvivo Perfusion Ab
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":976,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/f5712d04101de56202d3e9206fb8c2b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MLKrcNK3F2EtzRBfPIgwYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1Mg--/https://media.zenfs.com/en/business-wire.com/f5712d04101de56202d3e9206fb8c2b7","width":960,"height":252},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/65wtjXc18_mofXA334yUPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE5NTI7aD01MTI-/https://media.zenfs.com/en/business-wire.com/f5712d04101de56202d3e9206fb8c2b7","width":976,"height":256}},"lazy":false},{"type":"text","content":"Preliminary results suggest potential to support extended preservation time and donor heart utilization","length":103,"tagName":"p","attribs":{}},{"type":"text","content":"TORONTO, April 22, 2026--(BUSINESS WIRE)--XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation time outside of the body. XVIVO intends to submit the results to the U.S. Food and Drug Administration (FDA) as part of the Pre-Market Approval (PMA) process later this year.","length":691,"tagName":"p"},{"type":"text","content":"HOPE is an investigational preservation method that circulates a cold, oxygenated solution through the organ to support preservation prior to transplant. It is being studied as an alternative to static cold storage.","length":215,"tagName":"p"},{"type":"text","content":""For decades, organ preservation has been a limiting factor in heart transplantation, with approximately one in three DBD and one in five DCD hearts ultimately being transplanted," said Victor Pretorius, M.D., Cardiothoracic and Thoracic Surgery at Emory Healthcare, and Principal Investigator of the PRESERVE Trial. "The results of the PRESERVE Trial are encouraging. Through HOPE, XVIVO Heart Assist Transport is being studied for the potent...